Xeris Biopharma Holdings (XERS) Income from Continuing Operations (2020 - 2026)

Xeris Biopharma Holdings has reported Income from Continuing Operations for 7 years, with the latest figure at 2234000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 124.23% year-over-year to 2234000.0; the trailing twelve-month figure through Mar 2026 stood at 12008000.0 (up 126.64% YoY), and the FY2025 full-year result was 554000.0, up 101.01% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 2234000.0, down from 11081000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 11081000.0 in Q4 2025, with the low at 33714000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 12291941.18 across 5 years, with a median of 13390000.0 in 2023.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 83.12% — and 2025, when it surged 316.72%.
• Xeris Biopharma Holdings' Income from Continuing Operations stood at 12930000.0 in 2022, then decreased by 3.56% to 13390000.0 in 2023, then soared by 61.81% to 5113000.0 in 2024, then surged by 316.72% to 11081000.0 in 2025, then tumbled by 79.84% to 2234000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2234000.0 (Q1 2026), 11081000.0 (Q4 2025), and 621000.0 (Q3 2025), per Business Quant data.